References: Hair growth and hair loss
Br J Dermatol. 1990 Nov;123(5):557-67.
Immunobiological studies on the alopecic (DEBR) rat.
Michie HJ, Jahoda CA, Oliver RF, Poulton TA.
Department of Pathology, Ninewells Hospital, Dundee, U.K.
The Dundee experimental bald rat (DEBR) has been proposed as an animal model of human alopecia areata, which is suspected of being an autoimmune disease. This study was carried out to establish whether the immunological changes observed in the lesional DEBR rat correlated with studies of human alopecia areata. The immune infiltrate was characterized using immunoperoxidase techniques on cryostat sections of vibrissa follicles. Indirect immunofluorescence was used to quantify the peripheral blood leucocytes. Some parallels were observed in the infiltration of human and DEBR rat follicles by T lymphocytes. In contrast, pre-lesional DEBR rat follicles, which are not available for investigation in human alopecia areata, were not penetrated by leucocytes and MHC class II antigens were expressed in the precortical region of the epidermal component of these follicles. Quantification of peripheral blood leucocytes showed significant increases in both T-lymphocyte subsets during lesional expression. We consider that the pre-lesional form of the rat may provide important information as a model for the pre-lesional and uninvestigated form of alopecia areata in man.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2147388&dopt=Abstract
Gan To Kagaku Ryoho. 1990 May;17(5):1015-20.
[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer]
[Article in Japanese]
Itami S, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Mizunuma N, Nakagawa K, et al.
Dept. of Clinical Oncology, Cancer Institute Hospital.
Twenty patients with advanced non-small cell lung cancer were treated with a combination chemotherapy consisting of ifosfamide (IFX), cisplatin (CDDP) and vindesine (VDS). The treatment schedule was IFX 1.3 g/m2 i.v., on days 1-5, CDDP 20 mg/m2 i.v., on days 1-5, and VDS 3 mg/m2 i.v., on days 1 & 8, and, in principle, the regimen was repeated every 4 weeks. Of 19 evaluable patients, there were 1 CR, 7 PR, 10 NC and 1 PD, with an overall response rate of 42.1%. The median duration of responses was 7.45 months, and the median survival time of all patients was 13.2 months. The major toxicities occurring were hematologic toxicity, alopecia, gastrointestinal toxicity and peripheral neuropathy. Hematologic toxicity was severe and was judged to be dose limiting, but clinically manageable. These results indicate that this combination chemotherapy is active against non-small cell lung cancer and deserves further studies.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2159265&dopt=Abstract
Invest New Drugs. 1990 May;8(2):215-9.
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Falkson G, Chasen MR, Falkson HC.
Department of Medical Oncology, University of Pretoria, South Africa.
Fifty patients with histologically confirmed advanced malignancies were treated with ifosfamide and mesna plus other cytostatics. The other cytostatic drugs added to the treatment regimen were cisplatin (36 pts), etoposide (31 pts) and doxorubicin (20 pts). Among previously untreated patients objective response was documented in 12 of 19 pts with ovarian cancer, 9 of 14 with small cell cancer of the lung and in all 3 pts with Ewing's sarcoma. Among patients with disease refractory to prior cytostatic treatment, objective response was documented in 8 of 9 with testicular cancer, 1 of 3 with high grade lymphoma and 0 of 2 with osteosarcoma. Side-effects due to the combination of ifosfamide plus mesna and other cytostatics were acceptable. No life-threatening or lethal toxicities occurred. Most commonly encountered toxicities were leukopenia (64%), nausea and vomiting (84%), alopecia (63%), CNS toxicity (30%) and renal toxicity (12%).
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2166721&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||